Identify potential early,
partner aggressively,
think globally

Qiming Venture Partners USA strives to be the investor of choice for top entrepreneurs. As a trusted and engaged partner, we bring more than capital to our portfolio companies. We believe that by working side-by-side and rolling-up our sleeves, together, we can deliver transformative technologies to patients, with superior outcomes.

We are proud to be working with such committed teams.

Acquired

Armo Biosciences

ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. In May 2018,  Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction.

Cadent Therapeutics

Cadent Therapeutics is rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. SK channels and NMDA receptors are ion channels that are critical for modulating the strength, timing, and integration of communication between and within neurons and neuronal networks in the central nervous system. 

Cardialen

Cardialen is developing an implantable defibrillator using low-electrical energy to restore normal heart rhythm and potentially avoid the negative side-effects of current therapies.

Kezar Life Sciences

Kezar Life Sciences ((NASDAQ: KZR)  is a clinical-stage biotechnology company, discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. Our lead product candidate, KZR-616, a first-in-class selective immunoproteasome inhibitor, has completed testing in healthy volunteers and is now enrolling a Phase 1b/2 clinical trial in lupus and lupus nephritis. 

Let’s Get Checked

LetsGetChecked is all about personal health testing, making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple but powerful way and giving greater control of their personal health.

Madaket

Madaket automates the manual, error-prone process of enrolling in Electronic Funds Transfer (EFT), Electronic Remittance Advice (ERA), Electronic Data Interchange for Claims (EDI) and other common provider-payer transactions. The result is less paperwork and faster payments for hospitals, health systems, and private practices.

My Health Teams

MyHealthTeams creates social networks for communities of people facing chronic conditions (everything from Lupus and multiple sclerosis, to autism, breast cancer, and COPD). We believe that when people facing the same chronic condition are able to connect with and learn from each other, ask questions, get referrals and share tips with other people who personally understand what it’s like to face that condition, health outcomes improve.

Platelet Biogenesis

Platelet BioGenesis is a Harvard University spinout that is making human platelets from stem cells. We have developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human pluripotent stem cell cultures. By removing the volunteer donor, we can make platelets that are cheaper, safer, and available on demand.

Acquired

Twine Health

The Twine Health platform brings a scalable approach to health coaching, allowing a single coach to work with a large number of patients, driving efficiencies while helping more people reach their goals. In February 2018, Fitbit, Inc. (NYSE: FIT) the leading global wearables brand, announced that it will acquire Twine Health.

WindMIL Therapeutics

WindMIL harnesses the power of bone marrow derived lymphocytes to develop ground-breaking immunotherapies to treat cancer patients. Our lead program is in a Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILsTM advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.

ZappRX

ZappRx is a digital health company offering a prescription and prior authorization (“PA”) platform; our goal is to streamline and increase efficiencies in the way specialty medications reach patients. We provide a secure, collaborative online platform that allows patients, physicians, and pharmacists to work together to improve patients’ access to treatment and deliver medicine faster.

Who We Are

Qiming Venture Partners was founded in China in 2006 and has over $4 billion in total assets under management. In January 2017, Qiming launched Qiming USA, focused on early-stage healthcare opportunities in the United States and Europe. Situated in the major life science hubs of Cambridge, San Francisco Bay Area and Seattle, we invest in highly disruptive platforms and products addressing significant unmet medical needs, driven by passionate and committed teams with the depth and experience to succeed.

Our Approach

Our conviction areas combine high market potential, in-depth team knowledge, and strong US-China synergies. We invest in disruptive technologies, platforms, and products that address significant unmet needs. We enjoy working with passionate and committed teams with the vision to transform healthcare and improve patient’s lives. Working together, we can achieve outstanding returns for our investors.

Therapeutics

Therapeutics

  • Our core conviction areas:
    • Cell & Gene Therapy
    • Neuroscience
  • Beyond our core conviction areas:
    • Oncology
    • Autoimmune disorders
    • Other breakthrough technologies

Digital Health

Digital Health

  • Our core conviction areas
    • Reduce friction in patient, payer, pharma, and provider interfaces
    • Invest alongside strategic investors
    • AI-enabled connected devices with the goals of optimizing user experience, reducing error, and improving cost-effectiveness

MedTech

MedTech

  • Our core conviction areas
    • Minimally invasive solutions for gap between drug and open surgery
    • Neuromediation
    • AI-enabled connected devices with the goals of optimizing user experience, reducing error, and improving cost-effectiveness

Our highly complementary team seeks to support entrepreneurs in their pursuit of healthcare innovation.

Anna French

Principal

Anna is a Principal at Qiming Venture Partners USA, focused on healthcare investing. Prior to joining Qiming, Anna was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations. She also led a global industry-academic consortium focused on cell therapy commercialization. Anna earned a D.Phil....

Anna is a Principal at Qiming Venture Partners USA, focused on healthcare investing. Prior to joining Qiming, Anna was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations. She also led a global industry-academic consortium focused on cell therapy commercialization. Anna earned a D.Phil from the University of Oxford, UK where her research focused on hematological differentiation of human induced pluripotent stem (iPS) cells. Anna has over 20 publications in the field of stem cell research.

QM US portfolio: Anna serves on the board of WindMIL Therapeutics and is a board observer with Let’s Get Checked, Cadent Therapeutics and Platelet Biogenesis.

Christopher Shen

Managing Partner

Prior to joining Qiming, Dr. Shen was a Managing Director and head of U.S. healthcare investing at Vertex Ventures Healthcare. Dr. Shen specializes in investments in biopharmaceutical and medical device companies. He has worked with seven companies that have since gone public or been successfully acquired, worth over US$2.1 billion in value. Notable past investments include...

Prior to joining Qiming, Dr. Shen was a Managing Director and head of U.S. healthcare investing at Vertex Ventures Healthcare. Dr. Shen specializes in investments in biopharmaceutical and medical device companies. He has worked with seven companies that have since gone public or been successfully acquired, worth over US$2.1 billion in value. Notable past investments include Twelve (acquired by Medtronic), Entellus Medical (acquired by Stryker), Nellix Endovascular (acquired by ELGX), Bridgepoint Medical (acquired by BSC), Evalve (acquired by Abbott), Glycomimetics (IPO), Ivantis, and Moximed.

Previously, Dr. Shen worked at Essex Woodlands, a healthcare-focused venture capital and private equity firm. Prior to joining Essex, he worked at New Enterprise Associates, one of the largest diversified venture capital firms. Previously, Dr. Shen held the position of Senior Design Engineer at Guidant Corporation’s Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. Dr. Shen also worked in Japan as a Design Engineer for Pfizer Inc.’s Strategic Innovation Group, an internal medical technology incubator.

Dr. Shen is the US Executive Director of the Singapore Stanford Biodesign Program and a Consulting Associate Professor of Medicine at Stanford University, focusing on medical technology innovation. He is also an Adjunct Professor at Stanford Business School. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology.

Dr. Shen received his MD, MBA, MS in Biomechanical Engineering and BS in Biological Sciences all from Stanford University.

QM US portfolio: Chris serves on the board of Cardialen

Gary Rieschel

Founding Managing Partner

Gary Rieschel has over twenty-five years of successful operating and investing experience as a senior executive, entrepreneur, investor, and global business strategist. During his career, Mr. Rieschel held executive positions at Intel, Sequent Computer, Cisco Systems, and Softbank Corporation. Over the last 20 years as a venture capitalist, he led investments in 12 companies which grew to over $1B USD in market capitalization...

Gary Rieschel has over twenty-five years of successful operating and investing experience as a senior executive, entrepreneur, investor, and global business strategist. During his career, Mr. Rieschel held executive positions at Intel, Sequent Computer, Cisco Systems, and Softbank Corporation. Over the last 20 years as a venture capitalist, he led investments in 12 companies which grew to over $1B USD in market capitalization. Gary aided in the creation of the venture capital industry in China through sponsoring and founding several of China’s leading VC firms including Softbank China Ventures, SAIF Partners (2001), Ceyuan Ventures (2004), and Qiming Venture Partners (2006). He is Founding Managing Partner of Qiming, a firm with over $3B USD focused on early stage investments in China which is one of China’s premier VC firms. Mr. Rieschel’ s personal investment areas are Healthcare and Cleantech. He has sponsored investments in imaging systems (Alltech), clinical trial execution (Tigermed listed in 2013 in Shenzhen SZSE:300347), fuel cells (Bloom Energy), industrial waste water treatment (CSD Water and Sludge), clean coal technologies (LP Amina), smart meters (Hexin), bioengineering (Lanzatech). Qiming launched a U.S.-based health care fund in 2017.

Mr. Rieschel is well regarded as a mentor to entrepreneurs, founders, and other venture capitalists. He advised the China Greentech Initiative, and the Rocky Mountain Institute in its move to China. He actively supports the US China Clean Energy Forum, Asia Society, PERC (Property and Environmental Research), The Nature Conservancy, the Climate Leadership Council, and the Council on Foreign Relations, and the U.S. Olympic Foundation. Gary is a Trustee of Reed College. He served on the joint venture boards of Blackrock/Bank of China and Silicon Valley Bank/Shanghai Pudong Development Bank. Gary passionately supports entrepreneurs and pragmatic technology solutions for the resource allocation and environmental issues the world faces today.

Gary holds a BA in Biology from Reed College in Portland, OR, and an MBA from the Harvard Business School. He lived in Japan for five years in the late 1980s and lived in Shanghai from 2005 through 2016. He now lives in Seattle, WA.

QM US portfolio: Gary serves on the board of Madaket Health

Jennifer Hu

Venture Partner

Before joining Qiming, Dr. Hu was VP and Head of (External) Innovation Center China at Bayer Healthcare, responsible for building and managing partnerships for Global Drug Discovery with organizations in Greater China. Prior to that, she was Director of Licensing & External Research at Merck&Co covering Greater China for Worldwide Licensing & External Research. She worked previously at Roche Palo...

Before joining Qiming, Dr. Hu was VP and Head of (External) Innovation Center China at Bayer Healthcare, responsible for building and managing partnerships for Global Drug Discovery with organizations in Greater China. Prior to that, she was Director of Licensing & External Research at Merck&Co covering Greater China for Worldwide Licensing & External Research.

She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics.

Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ. She is a board member of BayHelix and Chinese-American BioPharma Society (CABS).

QM US portfolio: Jennifer led our investment in ARMO BioSciences (acquired by Lilly)

Mark McDade

Managing Partner

Before joining Qiming in 2017, McDade was Executive Vice President, Chief Operating Officer at UCB. He led UCB’s worldwide Geographic Operations, Established Brands, Technical Operations and Business Development. He joined UCB’s Executive Committee in 2008. From 2002 until late 2007...

Before joining Qiming in 2017, Mr. McDade was Executive Vice President, Chief Operating Officer at UCB. He led UCB’s worldwide Geographic Operations, Established Brands, Technical Operations and Business Development. He joined UCB’s Executive Committee in 2008.

From 2002 until late 2007, Mr. McDade served as Chief Executive Officer and a director of PDL Biopharma, an antibody-based biopharma located in Redwood City, CA, USA. Prior to PDL, he served as CEO of Signature Bioscience, located in San Francisco, CA. Mark was founder and a director of Corixa Corporation, where he served as Chief Operating Officer from September 1994 to December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000 to join Signature. Before Corixa, Mark was COO of Boehringer Mannheim Therapeutics, the bio-pharmaceutical division of Corange, and prior to that held several positions at Sandoz Ltd. Including business development, product management and general management.

Mr. McDade serves on the Board of directors of FivePrime Therapeutics (FPRX), Dermira (DERM) and Aimmune Therapeutics (AIMT), all publicly traded biotechs in the SF Bay Area. Mark received a BA from Dartmouth College and an MBA from the Harvard Business School.

QM US portfolio: Mark serves on the boards of Cadent Therapeutics, Let’s Get Checked, myHealthteams, Platelet Biogenesis, WindMIL Therapeutics and ZappRx. He led our investments in Kezar Life Sciences (KZR) and Twine Health (acquired by FitBit (FIT)).

Fellowship

In honor of a colleague and friend…

A former colleague [of a Qiming US partner] and a true friend to the firm, Mohamed Chaoui, recently passed away following a battle with lung cancer. He has inspired us to create a rolling fellowship to help develop MBA, MD, Ph.D., PharmD or other advanced degree students with a unique Qiming US experience.

The application is simple. Along with your CV, send us an introduction sharing why you are interested, what you will bring to the table, and your optimal time period.

Check out the latest news about Qiming and our portfolio companies.

    Our US Locations

    Cambridge

    1 Broadway, 9th Floor
    Cambridge, MA 02142

    Seattle

    2101 4th Avenue,
    Suite 2300
    Seattle, WA 98121

    SF Bay Area

    108 First Street
    Los Altos, CA 94022